Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 10, 2024

Belzutifan for von Hippel–Lindau Disease–Associated Pancreatic Lesions

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Clin. Cancer Res 2024 Feb 23;[EPub Ahead of Print], T Else, E Jonasch, O Lliopoulos, KE Beckermann, V Narayan, BL Maughan, S Oudard, JK Maranchie, AB Iversen, CM Goldberg, W Fu, RF Perini, Y Liu, WM Linehan, R Srinivasan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading